ENZON PHARMACEUTICALS, INC.: A Radical Transformation Through Merger and Reverse Stock Split

ENZON PHARMACEUTICALS, INC. is undergoing a radical transformation. The company has announced two major developments: a 1-for-100 reverse stock split and a merger with Viskase Companies, Inc. Stockholders approved these actions, marking a complete strategic pivot for ENZON.

---

1. Event Overview: A Merger and Reverse Stock Split Reshape ENZON

ENZON's stockholders have given the green light to two big changes. First, they authorized a 1-for-100 reverse stock split. This means if you own 100 shares of ENZON stock, you'll now have 1 new share.

Second, and even more significantly, stockholders approved a plan for ENZON to merge with Viskase Companies, Inc. This complete merger brings ENZON together with Viskase, a global manufacturer of cellulose and plastic casings primarily used in the food industry for meat processing. This merger is a dramatic departure from ENZON's historical focus on pharmaceuticals.

The reverse stock split aims to boost ENZON's per-share trading price. This can help the company meet minimum price requirements for continued listing on certain stock exchanges and potentially attract bigger investors who often steer clear of "penny stocks." The merger with Viskase represents a fundamental shift in ENZON's business strategy. The combined company will primarily focus on Viskase's established food casing business, moving entirely away from ENZON's pharmaceutical roots.

2. Timeline and Approval Date

Stockholders approved these proposals on February 11, 2026. This date is when the proposals were approved, not when the merger or reverse split actually happened. The actual closing of the merger and the reverse split will occur at a later, unannounced date, and they're subject to various closing conditions.

3. Financial Implications

• Reverse Stock Split: The 1-for-100 reverse stock split aims to increase ENZON's per-share trading price. While your total holdings should theoretically maintain the same value right after the split (for example, 100 shares at $0.10 become 1 share at $10.00), market dynamics can always cause fluctuations.
• Merger with Viskase: The company didn't share much detail about the exact financial impact of the merger in this initial filing. Important financial details, like how many Viskase shares you'll get for your ENZON shares, what kind of cost savings or growth they expect, and Viskase's own financial performance, aren't in this filing. You'll need to look at the full merger documents (like the Form S-4) for that. The company hasn't yet laid out the specific financial benefits of bringing a pharma company and a food casing manufacturer together, like potential cost savings or new market opportunities. So, we don't know the full picture there yet.
• Market Listing Change: The combined company's stock is expected to trade on the OTCQB tier of the OTC market. This typically means lower liquidity (it might be harder to buy or sell shares quickly), potentially wider bid-ask spreads (a bigger difference between what buyers are willing to pay and sellers are willing to accept), and less stringent reporting requirements compared to a major exchange. This shift can affect who can invest and how the market views the stock, potentially impacting its value.

4. Impact Assessment

• Investors/Shareholders: This transaction completely overhauls your investment. Your post-split ENZON shares will convert into shares of Viskase Companies, Inc. This summary doesn't tell us the exact exchange ratio – meaning how many Viskase shares you'll get for each ENZON share you own. That's a super important detail you'll need to find in the full merger documents. You will shift from investing in a pharmaceutical company to a food casing manufacturer.
• The Combined Company: The new entity will primarily operate as Viskase Companies, Inc., focusing on food casings. The company hasn't announced the new company's name, who will be in charge, or the specific plans for how they'll operate yet.
• ENZON's Pharmaceutical Business: What happens to ENZON's current pharmaceutical products and projects isn't clear yet. Investors will need to find out if these assets will be sold off, spun out, or somehow integrated into the new food casing business. The company didn't provide much detail about this in their filing.
• Employees & Customers: The company expects significant changes for ENZON's employees. The impact on its pharmaceutical customers and patients will depend on the ultimate fate of its drug portfolio.

5. Key Takeaways for Investors

• Merger Closing Conditions: The merger is subject to the usual closing conditions, like getting regulatory approvals, sorting out financing, and other legal requirements. The company hasn't announced a definitive closing date.
• Essential Due Diligence: You absolutely must thoroughly review the Registration Statement on Form S-4 and the Prospectus/Consent Solicitation/Offer to Exchange. These documents will provide vital information, including the specific reasons for this strategic move, the anticipated benefits of combining these very different businesses, and details on the combined company's management team and board of directors.
• Risks: This transaction carries substantial risks. Beyond the general challenges of integrating any two companies, specific risks include:
  • The difficulty of integrating two companies from vastly different industries (pharma and food casings).
  • Potential loss of focus on ENZON's pharmaceutical assets, whatever their fate.
  • Regulatory hurdles specific to the food industry.
  • The possibility that anticipated synergies or strategic benefits may not materialize as hoped.

This represents a complete transformation for ENZON PHARMACEUTICALS, INC. As an investor, you need to do extensive due diligence to fully understand the new business, its financial prospects, and the altered risk profile before making any investment decisions.